ArticleAmerican journal of cancer research2025
Comparative effects of oxaliplatin-based versus irinotecan-based regimens combined with capecitabine and bevacizumab in patients with colorectal cancer and liver metastases.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk prediction model for severe potential drug-drug interactions in colorectal cancer patients: a real-world data study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate and compare the efficacy of oxaliplatin-based and irinotecan-based chemotherapy regimens, both combined with capecitabine and bevacizumab, in patients with colorectal cancer and liver metastases.
methodsA retrospective analysis was conducted on 276 patients from Shanxi Province Cancer Hospital. Patients were divided into two groups (n = 138 each) based on treatment regimens. The control group received irinotecan hydrochloride, capecitabine, and bevacizumab, while the research group received oxaliplatin, capecitabine, and bevacizumab. Outcomes compared included overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS), serum vascular endothelial growth factor (VEGF), carbohydrate antigen 19-9 (CA19-9), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP), immunoglobulin levels (IgM, IgG), quality of life (QoL), pain scores (VAS), and adverse reactions.
resultsThe research group showed significantly higher ORR (21.74%) and DCR (63.77%) than the control group (12.32% and 50.00%, respectively; both P < 0.05). One-year PFS, and OS were all significantly improved in the research group (both P < 0.05). Post-treatment, VEGF, CA19-9, LDH, and ALP levels decreased significantly in both groups, with greater reductions in the research group (all P < 0.05). The research group also reported lower VAS pain scores, better QoL improvements, higher IgM and IgG levels, and a lower incidence of adverse reactions (all P < 0.05).
conclusionThe oxaliplatin-based regimen significantly improves tumor control, biomarker profiles, survival, and patient well-being, with fewer adverse effects, supporting its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.